Cargando…
The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective
Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society of Musculoskeletal and Neuronal Interactions
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919663/ https://www.ncbi.nlm.nih.gov/pubmed/35234161 |
_version_ | 1784668979778813952 |
---|---|
author | Chinoy, Amish Vassallo, Grace R. Wright, Emma Burkitt Eelloo, Judith West, Siobhan Hupton, Eileen Galloway, Paula Pilkington, Amy Padidela, Raja Mughal, M. Zulf |
author_facet | Chinoy, Amish Vassallo, Grace R. Wright, Emma Burkitt Eelloo, Judith West, Siobhan Hupton, Eileen Galloway, Paula Pilkington, Amy Padidela, Raja Mughal, M. Zulf |
author_sort | Chinoy, Amish |
collection | PubMed |
description | Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children with NF1 are unable to undertake physical activities to the same level as their peers, and report leg pains on physical activity and aching hands on writing. Children and adolescents with NF1 reporting symptoms of muscle weakness should have a focused assessment to exclude alternative causes of muscle weakness. Assessments of muscle strength and fine motor skills by physiotherapists and occupational therapists can provide objective evidence of muscle function and deficits, allowing supporting systems in education and at home to be implemented. In the absence of an evidence base for management of NF1-related muscle weakness, we recommend muscle-strengthening exercises and generic strategies for pain and fatigue management. Currently, trials are underway involving whole-body vibration therapy and carnitine supplementation as potential future management options. |
format | Online Article Text |
id | pubmed-8919663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | International Society of Musculoskeletal and Neuronal Interactions |
record_format | MEDLINE/PubMed |
spelling | pubmed-89196632022-04-14 The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective Chinoy, Amish Vassallo, Grace R. Wright, Emma Burkitt Eelloo, Judith West, Siobhan Hupton, Eileen Galloway, Paula Pilkington, Amy Padidela, Raja Mughal, M. Zulf J Musculoskelet Neuronal Interact Review Article Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children with NF1 are unable to undertake physical activities to the same level as their peers, and report leg pains on physical activity and aching hands on writing. Children and adolescents with NF1 reporting symptoms of muscle weakness should have a focused assessment to exclude alternative causes of muscle weakness. Assessments of muscle strength and fine motor skills by physiotherapists and occupational therapists can provide objective evidence of muscle function and deficits, allowing supporting systems in education and at home to be implemented. In the absence of an evidence base for management of NF1-related muscle weakness, we recommend muscle-strengthening exercises and generic strategies for pain and fatigue management. Currently, trials are underway involving whole-body vibration therapy and carnitine supplementation as potential future management options. International Society of Musculoskeletal and Neuronal Interactions 2022 /pmc/articles/PMC8919663/ /pubmed/35234161 Text en Copyright: © Journal of Musculoskeletal and Neuronal Interactions https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Chinoy, Amish Vassallo, Grace R. Wright, Emma Burkitt Eelloo, Judith West, Siobhan Hupton, Eileen Galloway, Paula Pilkington, Amy Padidela, Raja Mughal, M. Zulf The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective |
title | The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective |
title_full | The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective |
title_fullStr | The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective |
title_full_unstemmed | The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective |
title_short | The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective |
title_sort | skeletal muscle phenotype of children with neurofibromatosis type 1 – a clinical perspective |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919663/ https://www.ncbi.nlm.nih.gov/pubmed/35234161 |
work_keys_str_mv | AT chinoyamish theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT vassallogracer theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT wrightemmaburkitt theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT eelloojudith theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT westsiobhan theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT huptoneileen theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT gallowaypaula theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT pilkingtonamy theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT padidelaraja theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT mughalmzulf theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT chinoyamish skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT vassallogracer skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT wrightemmaburkitt skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT eelloojudith skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT westsiobhan skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT huptoneileen skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT gallowaypaula skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT pilkingtonamy skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT padidelaraja skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective AT mughalmzulf skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective |